REPLIGEN CORP Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
REPLIGEN CORP (RGEN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $119.57 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-07-29
- REPLIGEN CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $125.03, a 19.53% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $155.38, a 19.41% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $192.80, a 6.50% increase year-over-year.
- REPLIGEN CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $181.03, a 4.32% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $141.38, a 18.35% decline from fiscal 2024.
- REPLIGEN CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $173.16, a 2.94% increase from fiscal 2023.
- REPLIGEN CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $168.22, a 11.88% decline from fiscal 2022.
- REPLIGEN CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $190.90, a 5.90% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $119.57 10-Q · filed 2026-07-29 | |||
| 2026-03-31 | $125.03 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $141.38 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $140.60 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $141.95 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $155.38 10-Q · filed 2025-04-29 | |||
| 2024-12-31 | $173.16 10-K · filed 2025-03-14 | |||
| 2024-09-30 | $175.60 10-Q · filed 2024-11-18 | |||
| 2024-06-30 | $184.66 10-Q/A · filed 2024-11-18 | |||
| 2024-03-31 | $192.80 10-Q/A · filed 2024-11-18 | |||
| 2023-12-31 | $168.22 10-K/A · filed 2024-11-18 | |||
| 2023-09-30 | $173.08 10-Q/A · filed 2024-11-18 | |||
| 2023-06-30 | $175.75 10-Q/A · filed 2024-11-18 | |||
| 2023-03-31 | $181.03 10-Q/A · filed 2024-11-18 | |||
| 2022-12-31 | $190.90 10-K · filed 2023-02-22 | |||
| 2022-09-30 | $180.82 10-Q · filed 2022-11-01 | |||
| 2022-06-30 | $180.82 10-Q · filed 2022-08-02 | |||
| 2022-03-31 | $189.21 10-Q · filed 2022-04-27 | |||
| 2021-12-31 | $202.88 10-K · filed 2022-02-17 | |||
| 2021-09-30 | $202.88 10-Q · filed 2021-10-28 | |||
| 2021-06-30 | $203.98 10-Q · filed 2021-07-27 | |||
| 2021-03-31 | $215.58 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | $115.81 10-K · filed 2021-02-24 | |||
| 2020-09-30 | $104.61 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $100.53 10-Q · filed 2020-07-30 | |||
| 2020-03-31 | $86.10 10-Q · filed 2020-05-06 | |||
| 2019-12-31 | $64.14 10-K · filed 2020-02-26 | |||
| 2019-09-30 | $61.98 10-Q · filed 2019-10-31 | |||
| 2019-06-30 | $61.98 10-Q · filed 2019-08-01 | |||
| 2019-03-31 | $59.52 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $35.48 10-K · filed 2019-03-01 | |||
| 2018-09-30 | $34.79 10-Q · filed 2018-11-01 | |||
| 2018-06-30 | $34.48 10-Q · filed 2018-08-02 | |||
| 2018-03-31 | $33.85 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | $33.38 10-K · filed 2018-02-22 | |||
| 2017-09-30 | $33.38 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $33.38 10-Q · filed 2017-08-03 | |||
| 2017-03-31 | $32.40 10-Q · filed 2017-05-04 | |||
| 2016-12-31 | $27.12 10-K · filed 2017-02-23 | |||
| 2016-09-30 | $11.22 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $12.40 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | $13.44 10-Q · filed 2016-05-05 | |||
| 2015-12-31 | $15.23 10-K · filed 2016-02-25 | |||
| 2015-09-30 | $16.57 10-Q · filed 2015-11-05 | |||
| 2015-06-30 | $14.31 10-Q · filed 2015-08-06 | |||
| 2015-03-31 | $14.26 10-Q · filed 2015-05-08 | |||
| 2014-12-31 | $13.98 10-K · filed 2015-03-17 | |||
| 2014-09-30 | $13.10 10-Q · filed 2014-11-07 | |||
| 2014-06-30 | $12.37 10-Q · filed 2014-08-11 | |||
| 2014-03-31 | $11.14 10-Q · filed 2014-05-09 | |||
| 2013-12-31 | $7.24 10-K · filed 2014-03-14 | |||
| 2013-09-30 | $6.97 10-Q · filed 2013-11-08 | |||
| 2013-06-30 | $5.86 10-Q · filed 2013-08-07 | |||
| 2013-03-31 | $6.23 10-Q · filed 2013-05-07 | |||
| 2012-12-31 | $3.65 10-K · filed 2013-03-15 | |||
| 2012-09-30 | $3.57 10-Q · filed 2012-11-08 | |||
| 2012-06-30 | $1.89 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |